Published in Shock on October 01, 2014
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
A good death. Intensive Care Med (2006) 2.52
Potential cellular and molecular causes of hypertrophic scar formation. Burns (2008) 2.39
Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg (2012) 2.13
Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients. Crit Care (2006) 2.01
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat (2005) 1.98
Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc (2003) 1.97
Mean glucose level is not an independent risk factor for mortality in mixed ICU patients. Intensive Care Med (2006) 1.76
Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Crit Care (2006) 1.70
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release (2003) 1.63
Quality of interhospital transport of critically ill patients: a prospective audit. Crit Care (2005) 1.57
Pleiotropic effects of angiopoietin-2 deficiency do not protect mice against endotoxin-induced acute kidney injury. Nephrol Dial Transplant (2012) 1.55
Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients: Response to Plank et al. Diabetes Care (2006) 1.55
Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med (2002) 1.49
Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med (2014) 1.48
A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem (2004) 1.47
Quality of interhospital transport of the critically ill: impact of a Mobile Intensive Care Unit with a specialized retrieval team. Crit Care (2011) 1.46
Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target? Crit Care (2009) 1.45
Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care (2009) 1.41
Adjunct nitrous oxide normalizes vascular reactivity changes after hemorrhagic shock in mice under isoflurane anesthesia. Anesthesiology (2009) 1.40
Tumor vessel biology in pediatric intracranial ependymoma. J Neurosurg Pediatr (2010) 1.38
Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes (2008) 1.36
Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol (2005) 1.32
Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med (2007) 1.32
Inter-hospital transport of critically ill patients; expect surprises. Crit Care (2012) 1.31
Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine (2011) 1.29
Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol (2008) 1.26
Liposome opsonization. J Liposome Res (2005) 1.26
Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem (2002) 1.22
A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther (2004) 1.22
Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res (2007) 1.20
Prone positioning of patients with acute respiratory failure. N Engl J Med (2002) 1.18
Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Med (2010) 1.18
Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol (2012) 1.16
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun (2005) 1.16
In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res (2002) 1.15
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
Relationship between duration of brain death and hemodynamic (in)stability on progressive dysfunction and increased immunologic activation of donor kidneys. Kidney Int (2003) 1.10
Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin. Vascul Pharmacol (2006) 1.08
Augmented renal clearance in critically ill: advantage or threat. Crit Care Med (2014) 1.08
Severe sepsis: stay and play or scoop and run? Am J Respir Crit Care Med (2013) 1.07
Early organ-specific endothelial activation during hemorrhagic shock and resuscitation. Shock (2008) 1.07
Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia (2005) 1.07
Back to basics in sepsis treatment: critically ill patients need intensive care. Crit Care (2014) 1.06
Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. J Hepatol (2005) 1.05
Shock-induced stress induces loss of microvascular endothelial Tie2 in the kidney which is not associated with reduced glomerular barrier function. Am J Physiol Renal Physiol (2009) 1.04
Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol (2005) 1.03
Preventable mortality evaluation in the ICU. Crit Care (2012) 1.02
Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study. Int J Cancer (2002) 1.02
RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood (2011) 1.02
Hyperglycaemia in critically ill patients: marker or mediator of mortality? Crit Care (2006) 1.01
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg (2009) 1.00
Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol (2007) 0.99
Ultrasound of the lung: just imagine. Intensive Care Med (2003) 0.99
Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol (2007) 0.99
FOXO3 modulates endothelial gene expression and function by classical and alternative mechanisms. J Biol Chem (2010) 0.98
Glutamine and antioxidants in critically ill patients. N Engl J Med (2013) 0.96
Oxygen therapy for sepsis patients in the emergency department: a little less? Eur J Emerg Med (2014) 0.96
Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. Blood (2008) 0.96
Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res (2008) 0.96
Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. ChemMedChem (2006) 0.96
Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol Pharm (2007) 0.95
The flow dependency of Tie2 expression in endotoxemia. Intensive Care Med (2013) 0.95
Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug Chem (2006) 0.95
Disseminated Rhodococcus equi infection in a kidney transplant patient without initial pulmonary involvement. Diagn Microbiol Infect Dis (2009) 0.95
An 18-year-old man with rapidly progressive multiorgan failure after a positive mononucleosis spot test result. Chest (2006) 0.95
The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology (2008) 0.93
Vascular bed-specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle. Blood (2010) 0.93
Physician staffing models and patient safety in the ICU. Chest (2009) 0.92
Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. J Immunol (2002) 0.92
Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol Biochem (2011) 0.92
Burnout exists: cut the fuel and use the fire hose. JAMA Intern Med (2013) 0.91
Adiponectin diminishes organ-specific microvascular endothelial cell activation associated with sepsis. Shock (2012) 0.91
Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. Wound Repair Regen (2011) 0.90
A human model of intra-abdominal hypertension: even slightly elevated pressures lead to increased acute systemic inflammation and signs of acute kidney injury. Crit Care (2013) 0.88
Lung transplantation for ventilator-dependent respiratory failure. J Heart Lung Transplant (2009) 0.88
Interactions between blood-borne Streptococcus pneumoniae and the blood-brain barrier preceding meningitis. PLoS One (2013) 0.88